Cancer Letters
Volume 243, Issue 2 , Pages 160-169 , 18 November 2006

Prolactin and breast cancer risk

  • Shelley S. Tworoger

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, 3rd Floor, Boston, MA 02115, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
    • Corresponding Author InformationCorresponding author. Address: Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, 3rd Floor, Boston, MA 02115, USA. Tel.: +1 617 525 2087; fax: +1 617 525 2008.
    • ,
  • Susan E. Hankinson

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, 3rd Floor, Boston, MA 02115, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA

Received 14 December 2005 ,Revised 27 January 2006 ,Accepted 30 January 2006.

References 

  1. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 2000;80:1523–1631
  2. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr. Rev. 2003;24:1–27
  3. Ganong WF. Review of Medical Physiology. 21st ed.. Los Altos, CA/NY: Lange Medical Books/McGraw-Hill; 2001;2001 pp
  4. Nussey S, Whitehead S. Endocrinology: An Integrated Approach. Oxford: BIOS Scientific Publishers Ltd; 2001;2001 pp
  5. Gellersen B, Kempf R, Telgmann R, DiMattia GE. Nonpituitary human prolactin gene transcription is independent of pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol. Endocrinol. 1994;8:356–373
  6. Clevenger CV, Chang WP, Ngo W, Pasha TL, Montone KT, Tomaszewski JE. Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am. J. Pathol. 1995;146:695–705
  7. Montgomery DW, LeFevre JA, Ulrich ED, Adamson CR, Zukoski CF. Identification of prolactin-like proteins synthesized by normal murine lymphocytes. Endocrinology. 1990;127:2601–2603
  8. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 2005;26:400–422
  9. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J. Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J. Clin. Invest. 1997;100:2744–2751
  10. Fields K, Kulig E, Lloyd RV. Detection of prolactin messenger rna in mammary and other normal and neoplastic tissues by polymerase chain reaction. Lab. Invest. 1993;68:354–360
  11. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology. 1997;138:5555–5560
  12. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res. 1995;55:2591–2595
  13. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, et al. Prolactin as a local growth promoter in patients with breast cancer: Gcri experience. Eur. J. Surg. Oncol. 2000;26:540–547
  14. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by mda-mb-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res. Treat. 2003;79:241–252
  15. Gutzman JH, Miller KK, Schuler LA. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells. J. Steroid Biochem. Mol. Biol. 2004;88:69–77
  16. Schroeder MD, Symowicz J, Schuler LA. Prl modulates cell cycle regulators in mammary tumor epithelial cells. Mol. Endocrinol. 2002;16:45–57
  17. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer. 2004;91:305–311
  18. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology. 1999;140:5447–5450
  19. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc. Natl Acad. Sci. USA. 1999;96:1246–1251
  20. Chakravarti P, Henry MK, Quelle FW. Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells. Int. J. Oncol. 2005;26:509–514
  21. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hprl-g129r, inhibits breast cancer cell proliferation through induction of apoptosis. Clin. Cancer Res. 1999;5:3583–3593
  22. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, et al. Human prolactin (hprl) antagonists inhibit hprl-activated signaling pathways involved in breast cancer cell proliferation. Oncogene. 2000;19:4695–4705
  23. Brockman JL, Schroeder MD, Schuler LA. Prl activates the cyclin d1 promoter via the jak2/stat pathway. Mol. Endocrinol. 2002;16:774–784
  24. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces eralpha-positive and eralpha-negative mammary cancer in transgenic mice. Oncogene. 2003;22:4664–4674
  25. Goldhar AS, Vonderhaar BK, Trott JF, Hovey RC. Prolactin-induced expression of vascular endothelial growth factor via egr-1. Mol. Cell. Endocrinol. 2005;232:9–19
  26. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 1998;83:667–674
  27. Meng J, Tsai-Morris CH, Dufau ML. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form human prolactin receptor associated with mammary carcinoma. Cancer Res. 2004;64:5677–5682
  28. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J. Clin. Pathol. 2001;54:956–960
  29. Ormandy CJ, Hall RE, Manning DL, Robertson JF, Blamey RW, Kelly PA, et al. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J. Clin. Endocrinol. Metab. 1997;82:3692–3699
  30. Glasow A, Horn LC, Taymans SE, Stratakis CA, Kelly PA, Kohler U, et al. Mutational analysis of the prl receptor gene in human breast tumors with differential prl receptor protein expression. J. Clin. Endocrinol. Metab. 2001;86:3826–3832
  31. Rae-Venter B, Nemoto T, Schneider SL, Dao TL. Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age. Breast Cancer Res. Treat. 1981;1:233–243
  32. Murphy LJ, Murphy LC, Vrhovsek E, Sutherland RL, Lazarus L. Correlation of lactogenic receptor concentration in human breast cancer with estrogen receptor concentration. Cancer Res. 1984;44:1963–1968
  33. Bonneterre J, Peyrat JP, Vandewalle B, Beuscart R, Vie MC, Cappelaere P. Prolactin receptors in human breast cancer. Eur. J. Cancer Clin. Oncol. 1982;18:1157–1162
  34. Bonneterre J, Peyrat JP, Beuscart R, Demaille A. Correlation between prolactin receptors (prl r), estradiol (er) and progesterone receptors (pgr) in human breast cancer. Eur. J. Cancer Clin. Oncol. 1986;22:1331–1336
  35. Waseda N, Kato Y, Imura H, Kurata M. Prognostic value of estrogen and prolactin receptor analysis in human breast cancer. Jpn. J. Cancer Res. 1985;76:517–523
  36. De Placido S, Gallo C, Perrone F, Marinelli A, Pagliarulo C, Carlomagno C, et al. Prolactin receptor does not correlate with oestrogen and progesterone receptors in primary breast cancer and lacks prognostic significance. Ten year results of the naples adjuvant (gun) study. Br. J. Cancer. 1990;62:643–646
  37. Ben-David M, Wittliff JL, Fekete M, Kadar T, Biran S, Schally AV. Lack of relationship between the levels of prolactin receptors and steroid receptors in women with breast cancer. Biomed. Pharmacother. 1988;42:327–334
  38. Mertani HC, Garcia-Caballero T, Lambert A, Gerard F, Palayer C, Boutin JM, et al. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int. J. Cancer. 1998;79:202–211
  39. Dhadly MS, Walker RA. The localization of prolactin binding sites in human breast tissue. Int. J. Cancer. 1983;31:433–437
  40. Kline JB, Roehrs H, Clevenger CV. Functional characterization of the intermediate isoform of the human prolactin receptor. J. Biol. Chem. 1999;274:35461–35468
  41. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhlikar PR, et al. Prognostic significance of immunohistochemically localized biomarkers in stage ii and stage iii breast cancer: a multivariate analysis. Ann. Surg. Oncol. 2000;7:305–311
  42. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA. Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol. Endocrinol. 2005;19:1765–1778
  43. Theodorakis SP, Tedesco VE, Sutherland CM. Breast cancer in a patient with prolactinoma. Surgery. 1985;98:367–369
  44. Buytaert P, Viaene P. Amenorrhea, galactorrhea, hyperprolactinemia syndrome and breast carcinoma in a young woman. Eur. J. Obstet. Gynecol. Reprod. Biol. 1981;11:341–346
  45. Volm MD, Talamonti MS, Thangavelu M, Gradishar WK. Pituitary adenoma and bilateral male breast cancer: an unusual association. J. Surg. Oncol. 1997;64:74–78
  46. Strungs I, Gray RA, Rigby HB, Strutton G. Two case reports of breast carcinoma associated with prolactinoma. Pathology. 1997;29:320–323
  47. Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, et al. Increased incidence of neoplasia in patients with pituitary adenomas. The pituitary study group. Clin. Endocrinol. (Oxf.). 1998;49:441–445
  48. Webster J. Clinical management of prolactinomas. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 1999;13:395–408
  49. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 2002;94:606–616
  50. Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Disordered nocturnal prolactin regulation in women with breast cancer. Cancer Res. 1977;37:4650–4654
  51. Rose DP, Pruitt BT. Plasma prolactin levels in patients with breast cancer. Cancer. 1981;48:2687–2691
  52. Abu-Bedair FA, El-Gamal BA, Ibrahim NA, El-Aaser AA. Hormonal profiles and estrogen receptors in egyptian female breast cancer patients. Tumori. 2000;86:24–29
  53. Cole EN, England PC, Sellwood RA, Griffiths K. Serum prolactin concentrations throughout the menstrual cycle of normal women and patients with recent breast cancer. Eur. J. Cancer. 1977;13:677–684
  54. Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J. Natl Cancer Inst. 1986;77:613–616
  55. Love RR, Rose DR, Surawicz TS, Newcomb PA. Prolactin and growth hormone levels in premenopausal women with breast cancer and healthy women with a strong family history of breast cancer. Cancer. 1991;68:1401–1405
  56. Ingram DM, Nottage EM, Roberts AN. Prolactin and breast cancer risk. Med. J. Aust. 1990;153:469–473
  57. Bernstein L, Ross RK, Pike MC, Brown JB, Henderson BE. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. Br. J. Cancer. 1990;61:298–302
  58. Anderson E, Morten H, Wang DY, Burns P, Birch J, Howell A. Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. Eur. J. Cancer Clin. Oncol. 1989;25:1719–1725
  59. Sheth NA, Ranadive KJ, Suraiya JN, Sheth AR. Circulating levels of prolactin in human breast cancer. Br. J. Cancer. 1975;32:160–167
  60. Drafta D, Schindler AE, Milcu SM, Keller E, Stroe E, Horodniceanu E, et al. Plasma hormones in pre- and postmenopausal breast cancer. J. Steroid Biochem. 1980;13:793–802
  61. Wilson RG, Buchan R, Roberts MM, Forrest AP, Boyns AR, Cole EN, et al. Plasma prolactin and breast cancer. Cancer. 1974;33:1325–1327
  62. Berger RL, Joison J, Braverman LE. Lactation after incision on the thoracic cage. N. Engl. J. Med. 1966;274:1493–1495
  63. Herman V, Kalk WJ, de Moor NG, Levin J. Serum prolactin after chest wall surgery: elevated levels after mastectomy. J. Clin. Endocrinol. Metab. 1981;52:148–151
  64. Bernardes JR, Nonogaki S, Seixas MT, Rodrigues de Lima G, Baracat EC, Gebrim LH. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int. J. Gynaecol. Obstet. 1999;67:33–38
  65. Kostoglou-Athanassiou I, Ntalles K, Gogas J, Markopoulos C, Alevizou-Terzaki V, Athanassiou P, et al. Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm. Res. 1997;47:116–120
  66. Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Fentiman IS, et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int. J. Epidemiol. 1992;21:214–221
  67. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in japanese women. Cancer Epidemiol. Biomarkers Prev. 2000;9:575–579
  68. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect. Prev. 1994;18:79–85
  69. S.S. Tworoger, P. Sluss, S.E. Hankinson, Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women, Cancer Res. 66 (2006) 2476–2482.
  70. Manjer J, Johansson R, Berglund G, Janzon L, Kaaks R, Agren A, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and shbg (Sweden). Cancer Causes Control. 2003;14:599–607
  71. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl Cancer Inst. 1999;91:629–634
  72. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 2004;64:6814–6819
  73. Lachelin GC, Yen SC, Alksne JF. Hormonal changes following hypophysectomy in humans. Obstet. Gynecol. 1977;50:333–339
  74. Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocr. Rev. 1995;16:354–369
  75. Hoffmann T, Penel C, Ronin C. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance. J. Endocrinol. Invest. 1993;16:807–816
  76. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli G, Sciajno R, et al. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol. Biomarkers Prev. 1996;5:917–922
  77. S.A. Missmer, D. Spiegelman, E.R. Bertone-Johnson, R.L. Barbieri, M.N. Pollak, S.E. Hankinson, Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2–3 year period, Cancer Epidemiol. Biomarkers Prev. (in press).
  78. Koenig KL, Toniolo P, Bruning PF, Bonfrer JM, Shore RE, Pasternack BS. Reliability of serum prolactin measurements in women. Cancer Epidemiol. Biomarkers Prev. 1993;2:411–414
  79. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C, Speizer FE. Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol. Biomarkers Prev. 1995;4:649–654
  80. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error. Am. J. Epidemiol. 1992;136:1400–1413
  81. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl Cancer Inst. 2004;96:1856–1865
  82. Wang DY, Sturzaker HE, Kwa HG, Verhofstad F, Hayward JL, Bulbrook RD. Nyctohemeral changes in plasma prolactin levels and their relationship to breast cancer risk. Int. J. Cancer. 1984;33:629–632
  83. Wang DY, de Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Verstraeten AA, et al. The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women. Eur. J. Cancer Clin. Oncol. 1988;24:1225–1231
  84. Kwa HG, Cleton F, Bulbrook RD, Wang DY, Hayward JL. Plasma prolactin levels and breast cancer: relation to parity, weight and height, and age at first birth. Int. J. Cancer. 1981;28:31–34
  85. Kwa HG, Wang DY. An abnormal luteal-phase evening peak of plasma prolactin in women with a family history of breast cancer. Int. J. Cancer. 1977;20:12–14
  86. Bernstein L, Pike MC, Ross RK, Judd HL, Brown JB, Henderson BE. Estrogen and sex hormone-binding globulin levels in nulliparous and parous women. J. Natl Cancer Inst. 1985;74:741–745
  87. Musey VC, Collins DC, Musey PI, Martino-Saltzman D, Preedy JR. Long-term effect of a first pregnancy on the secretion of prolactin. N. Engl. J. Med. 1987;316:229–234
  88. Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC. levels of prolactin in nulliparous women. Br. J. Cancer. 1981;43:826–831
  89. Hankinson SE, Colditz GA, Hunter DJ, Manson JE, Willett WC, Stampfer MJ, et al. Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the nurses' health study (United States). Cancer Causes Control. 1995;6:217–224
  90. Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease, Lancet 360 (2002) 187–195.
  91. Henderson BR, Gerkins V, Rosario I, Casagrande J, Pike MC. Elevated serum levels of estrogen and prolactin in daughters of patients with breast cancer. N. Engl. J. Med. 1975;293:790–795
  92. Levin PA, Malarkey WB. Daughters of women with breast cancer have elevated mean 24-hour prolactin (prl) levels and a partial resistance of prl to dopamine suppression. J. Clin. Endocrinol. Metab. 1981;53:179–183
  93. Love RR, Rose DP. Elevated bioactive prolactin in women at risk for familial breast cancer. Eur. J. Cancer Clin. Oncol. 1985;21:1553–1554
  94. Fishman J, Fukushima D, O'Connor J, Rosenfeld RS, Lynch HT, Lynch JF, et al. Plasma hormone profiles of young women at risk for familial breast cancer. Cancer Res. 1978;38:4006–4011
  95. Jernstrom HC, Olsson H, Borg A. Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19–25 years who were first and/or second degree relatives to breast cancer patients. Eur. J. Cancer Prev. 1997;6:330–340
  96. de Waard F, Kwa HG, Poortman J. Plasma prolactin levels in women at postmenopausal age with a family history of breast cancer or a prescription for antihypertensive rauwolfia treatment. Oncology. 1980;37:33–36
  97. Meyer F, Brisson J, Morrison AS, Brown JB. Endogenous sex hormones, prolactin, and mammographic features of breast tissue in premenopausal women. J. Natl Cancer Inst. 1986;77:617–620
  98. Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, et al. The association of breast mitogens with mammographic densities. Br. J. Cancer. 2002;87:876–882
  99. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 2005;14:2641–2647
  100. Kline JB, Clevenger CV. Identification and characterization of the prolactin-binding protein in human serum and milk. J. Biol. Chem. 2001;276:24760–24766
  101. Trott JF, Hovey RC, Koduri S, Vonderhaar BK. Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin-binding protein. J. Mol. Endocrinol. 2003;30:31–47

PII: S0304-3835(06)00094-2

doi: 10.1016/j.canlet.2006.01.032

Cancer Letters
Volume 243, Issue 2 , Pages 160-169 , 18 November 2006

Article Tools

* Image Usage & Resolution